Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative chemotherapy with or without bevacizumab in advanced ovarian cancer
2012-003883-31Phase 2Terminated
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in ovarian cancer (2 arms), sponsored by Grupo Español de Investigación en Cáncer de Ovario. Primary endpoint: Complete response rate after neoadjuvant therapy. Started Jan 2013; status: terminated.
02
Drugs
bevacizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2012-003883-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003883-31.